Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis has announced that it has entered into an agreement to acquire Chinook Therapeutics, a Seattle, WA, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic […]
Novartis to acquire Chinook Therapeutics Read More »
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting will feature
Janssen’s Transformational Cancer Care at ASCO and EHA Read More »
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation
Janssen Collaborates with CBMG to Develop CAR-T Therapies Read More »
Sanofi has simplified its contractual agreements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the U.S.
Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements Read More »
Pfizer Inc. and Seagen Inc. has announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both
Pfizer Invests $43 Billion to Battle Cancer Read More »
